




RealRate

PHARMACEUTICAL 2015

Madrigal Pharmaceuticals INC
Rank 176 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Madrigal Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Madrigal Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Madrigal Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 217%, being 37% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	99,346
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,889
Liabilities, Non-Current	4,650
Other Assets	305
Other Compr. Net Income	-2,223
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	1,024
Research and Development	68,205
Selling, General and Administrative Expense	15,746

Output Variable	Value in 1000 USD
Assets	100,675
Liabilities	35,539
Expenses	83,951
Revenues	0
Stockholders Equity	65,136
Net Income	-83,951
Comprehensive Net Income	-85,062
BaseVar	111,194
ECR before Limited Liability	84%
Economic Capital Ratio	217%